Countries used to test drugs often don’t see the approved medicines, study finds
Numerous medicines are not accessible in many of the countries where they were tested before approval by the…
China’s WuXi AppTec, after evading threat of U.S. ban, comes out ahead
For nearly two years, WuXi AppTec, the Chinese contract research giant with extensive ties with U.S. biotech and…
We’re reading about Trump and patent policies, a new malaria drug
Top of the morning to you, and a fine one it is. Blue skies and comfortable breezes are…
At AASLD, optimism about AI, Hep delta and Madrigal’s MASH drug
Isabella Cueto covers the leading causes of death and disability: chronic diseases. Her focus includes autoimmune conditions and…
CRISPR gene editing therapy cuts LDL cholesterol in small study
A CRISPR-based gene editing therapy dramatically reduced levels of low-density lipoprotein, often called “bad cholesterol,” and triglycerides in…
Merck’s experimental pill lowered bad cholesterol as much as shots
Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach…
Amgen’s Repatha cholesterol shot slashed heart attack risk by 36%
Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach…
UnitedHealthcare drops remote monitoring coverage
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
Researcher says $25 version of Gilead drug could eradicate HIV in USA
For the past few months, CVS Caremark has declined to add a groundbreaking HIV prevention drug from Gilead…
Medicare picks tech firms to run prior authorization pilot
The Centers for Medicare and Medicaid Services has selected the six technology companies that will administer artificial intelligence-powered…
Mark Cuban tries to shake up biosimilar pricing with a version of J&J’s Stelara
In its latest bid to shake up the prescription drug market, the Mark Cuban Cost Plus Drug Company…
New FDA priority review vouchers go to Lilly, Novo, Vertex
WASHINGTON — The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s…